{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kamai T"],"funding":["Japanese Science Progress Society KAKENHI Grants"],"pagination":["2009-2021"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8195893"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["70(7)"],"pubmed_abstract":["<h4>Background</h4>Adenosine and its adenosine 2A receptors (A2AR) mediate the immunosuppressive mechanism by which tumors escape immunosurveillance and impede anti-tumor immunity within the tumor microenvironment. However, we do not know whether the adenosine pathway (CD39/CD73/A2AR) plays a role in renal cell carcinoma (RCC). Therefore, we studied the role of immunosuppression in RCC by assessing the adenosine pathway in patients with RCC treated with anti-vascular endothelial growth factor (anti-VEGF) agents or immune checkpoints inhibitors (ICIs) or both.<h4>Methods</h4>In 60 patients with metastatic RCC, we examined the expression of CD39, CD73, A2AR, and programmed cell death 1 ligand 1 (PD-L1) immunohistochemically in surgically resected tumor tissues and studied the clinicopatholog"],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival."],"pmcid":["PMC8195893"],"funding_grant_id":["17K11156, 20K09546"],"pubmed_authors":["Kamai T","Tsuzuki T","Kijima T","Arai K","Yoshida KI","Nukui A","Abe H"],"additional_accession":[]},"is_claimable":false,"name":"Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.","description":"<h4>Background</h4>Adenosine and its adenosine 2A receptors (A2AR) mediate the immunosuppressive mechanism by which tumors escape immunosurveillance and impede anti-tumor immunity within the tumor microenvironment. However, we do not know whether the adenosine pathway (CD39/CD73/A2AR) plays a role in renal cell carcinoma (RCC). Therefore, we studied the role of immunosuppression in RCC by assessing the adenosine pathway in patients with RCC treated with anti-vascular endothelial growth factor (anti-VEGF) agents or immune checkpoints inhibitors (ICIs) or both.<h4>Methods</h4>In 60 patients with metastatic RCC, we examined the expression of CD39, CD73, A2AR, and programmed cell death 1 ligand 1 (PD-L1) immunohistochemically in surgically resected tumor tissues and studied the clinicopatholog","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2025-04-26T00:32:53.771Z","creation":"2022-02-10T16:47:41.973Z"},"accession":"S-EPMC8195893","cross_references":{"pubmed":["33416945"],"doi":["10.1007/s00262-020-02843-x"]}}